Indication
Triptorelin (Decapeptyl SR 3 mg), a gonadotropin-releasing-hormone (GnRH) agonist, is indicated as adjuvant treatment, in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.

Medicine details

Medicine name:
triptorelin acetate (Decapeptyl)
SMC ID:
SMC2186
Pharmaceutical company
Ipsen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
07 October 2019
SMC meeting date:
03 September 2019
Patient group submission deadline:
05 August 2019